5612 Results

People

  1. Giralt
    Giralt
  2. Ladanyi
    Ladanyi
  3. Arcila
    Arcila
  4. Perales
    Perales
  5. Drilon
    Drilon
  6. Hyman
    Hyman
  7. Berger
    Berger
  8. Solit
    Solit
  9. Motzer
    Motzer
  10. Reis-Filho
    Reis-Filho

Groups

  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)
  7. Center for Hematologic Malignancies (914)
  8. Survivorship Research (910)
  9. Department of Pathology and Laboratory Medicine (784)
  10. Population Sciences Research Program (751)
  1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: Results from Cohort 1
    Meeting Abstract

    Mellinghoff, I. K.; Wen, P. Y.; Taylor, J. W.; Maher, E. A.; Arrillaga-Romany, I.; Peters, K. B.; Le, K.; Tai, F.; Steelman, L.; Cloughesy, T. F.
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 trial evaluating safety, efficacy, and PK of AMG 510, a novel KRASG12C inhibitor, in non-small cell lung cancer
    Meeting Abstract

    Govindan, R.; Fakih, M. G.; Price, T. J.; Falchook, G. S.; Desai, J.; Kuo, J. C.; Strickler, J. H.; Krauss, J. C.; Li, B. T.; Denlinger, C. S.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • The TREAT model 2.0: Predicting lung cancer in patients seeking care in high-risk clinics
    Meeting Abstract

    Shipe, M.; Maiga, A.; Deppen, S.; Welty, V.; Blume, J.; Aldrich, M.; Montgomery, C.; Dickerson, A.; Crockett, J.; Vaszar, L.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Safety, efficacy, and pharmacokinetics of AMG 510, a novel KRAS(G12C) inhibitor, in patients with non-small cell lung cancer
    Meeting Abstract

    Govindan, R.; Fakih, M.; Price, T.; Falchook, G.; Desai, J.; Kuo, J.; Strickler, J.; Krauss, J.; Li, B.; Denlinger, C.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response
    Meeting Abstract

    Brahmer, J.; Horn, L.; Hossein, B.; Ramalingam, S.; Pluzanski, A.; Burgio, M. A.; Garassino, M. C.; Chow, L. Q. M.; Gettinger, S.; Crino, L.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Using next-generation sequencing to identify genetic predictors of local failure after lung stereotactic body radiation therapy
    Meeting Abstract

    Ng, V.; Rimner, A.; Sidiqi, B.; Wu, A.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Lurbinectedin (L) combined with paclitaxel (P) or irinotecan (I) in relapsed SCLC. Results from two phase Lb trials
    Meeting Abstract

    Ponce, S.; Calvo, E.; De Miguel, M. J.; Sessa, C.; Flor, M. J.; Drilon, A.; Falcon, A.; Sanchez Simon, I.; Nuñez, R.; Luepke, X. E.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Phase 1 study of CA-170: First-in-class small molecule targeting VISTA/PD-L1 in patients with malignant pleural mesothelioma
    Meeting Abstract

    Zauderer, M.; Brody, J.; Marron, T.; Pacey, S.; Martell, R.; Wang, H.; Spicer, J.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • IASLC global survey for pathologists on PD-L1 testing for non-small cell lung cancer
    Meeting Abstract

    Mino-Kenudson, M.; Redman, M.; Hedger, J.; Daigneault, J.; Botling, J.; Brambilla, E.; Chen, G.; Chou, T.; Cooper, W.; Hirsch, F. R.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Surgical outcomes of a multicenter phase II trial of neoadjuvant atezolizumab in resectable stages IB-IIIB NSCLC: Update on LCMC3 clinical trial
    Meeting Abstract

    Lee, J.; Chaft, J.; Nicholas, A.; Patterson, G.; Waqar, S.; Toloza, E.; Haura, E.; Raz, D.; Reckamp, K.; Merritt, R.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save